Document is current

Article History

Received: 6 March 2025

Accepted: 26 June 2025

First Online: 18 July 2025

Change Date: 15 August 2025

Change Type: Update

Change Details: The original version of this paper was updated to correct the identified errros, most notably around the naming of the MY PD-CARE tool and figure quality.

Declarations

:

: This study was conducted in accordance with the ethical principles originating in the European Medicines Agency Module XVI Guideline on Good Pharmacovigilance Practices. The study was approved by an independent ethics committee as required by local laws and regulations. All study participants provided written informed consent.

: AA has received compensation for consultancy and speaker-related activities from AbbVie, Bial, Boehringer Ingelheim, Britannia, Ever Pharma, General Electric, Jazz Pharmaceuticals, Kyowa Kirin, Medscape, Neuroderm, Roche, Theravance Biopharma, UCB, and Zambon; has received research support from Angelini Pharmaceuticals, Bial, Cariparo Foundation, Horizon 2020 Grant 825785, Horizon2020 Grant 101016902, Lundbeck, Ministry of Education University and Research (MIUR), Movement Disorders Society, and Roche; and reports consultancy services for Boehringer Ingelheim for legal cases on pathological gambling. TH has received speaker honoraria from AbbVie, Britannia, Convatec, Ever Pharma, Lundbeck, Neuroderm, and Nordic Infucare; serves as a principal investigator for a study sponsored by AbbVie; and serves on the data monitoring committee for a study sponsored by Lundbeck. AH has no conflict of interest to disclose. LB and JCP are full-time employees of AbbVie and may hold AbbVie stock and/or stock options. PO has received compensation for consultancy and speaker-related activities from AbbVie, Bial, Britannia, Ever Pharma, Nordic Infucare, Stada, and Zambon, and has received royalties from Uni-Med Verlag. The authors have no other relevant financial or non-financial interests to declare.